S&P TSX Capped Composite...

US Dollar vs CAD

Trade smarter, not harder: Unleash your inner pro with our toolkit and live discussions.

Get Started

ADCT ADC Therapeutics SA

1.65

0.07 (4.43%)

Feb 04 2025 - Closed

Delayed by 15 minutes

Form EFFECT - Notice of Effectiveness

ADC Therapeutics (NYSE:ADCT)
Historical Stock Chart
From Jan 2025 to Feb 2025

Click Here for more ADC Therapeutics Charts.

ADC Therapeutics (NYSE:ADCT)
Historical Stock Chart
From Feb 2024 to Feb 2025

Click Here for more ADC Therapeutics Charts.

ADC Therapeutics SA News

Form SCHEDULE 13G - Statement of Beneficial Ownership by Certain Investors
Monday 3 February 2025 (1 day ago) • Edgar (US Regulatory)

ADC Therapeutics Makes Grants to New Employees Under Inducement Plan
Monday 3 February 2025 (1 day ago) • PR Newswire (US)

ADC Therapeutics to Participate in the Guggenheim SMID Cap Biotech Conference
Thursday 30 January 2025 (6 days ago) • PR Newswire (US)

Form 8-K - Current report
Monday 13 January 2025 (3 weeks ago) • Edgar (US Regulatory)

ADC Therapeutics Makes Grants to New Employees Under Inducement Plan
Thursday 2 January 2025 (1 month ago) • PR Newswire (US)

ADC Therapeutics Announces Completion of Enrollment of Phase 3 Confirmatory Clinical Trial of ZYNLONTA® in Combination with Rituximab in 2L+ Diffuse Large B-Cell Lymphoma
Monday 30 December 2024 (1 month ago) • PR Newswire (US)

ADC Therapeutics Announces Positive Initial Data from LOTIS-7 Clinical Trial Evaluating ZYNLONTA® in Combination with Bispecific Antibody in Patients with Relapsed/Refractory Diffuse Large B-cell Lymphoma
Wednesday 11 December 2024 (2 months ago) • PR Newswire (US)

Form 4 - Statement of changes in beneficial ownership of securities
Monday 9 December 2024 (2 months ago) • Edgar (US Regulatory)

Form 4 - Statement of changes in beneficial ownership of securities
Monday 9 December 2024 (2 months ago) • Edgar (US Regulatory)

Form 4 - Statement of changes in beneficial ownership of securities
Monday 9 December 2024 (2 months ago) • Edgar (US Regulatory)

ADC Therapeutics Announces The Lancet Haematology Publication of Data from Investigator-Initiated Trial Evaluating ZYNLONTA® in Combination with Rituximab to Treat Relapsed/Refractory Follicular Lymphoma
Monday 9 December 2024 (2 months ago) • PR Newswire (US)

ADC Therapeutics to Provide Initial Data Update on LOTIS-7 Clinical Trial
Friday 6 December 2024 (2 months ago) • PR Newswire (US)

More ADC Therapeutics SA News Articles

ADC Therapeutics

Delayed Upgrade Clock

Support: +44 (0) 203 8794 460 | support@advfn.com

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions